BDRX
Price:
$3.91
Market Cap:
$725.07M
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug ...[Read more]
Industry
Biotechnology
IPO Date
2015-12-07
Stock Exchange
NASDAQ
Ticker
BDRX
According to Biodexa Pharmaceuticals Plc’s latest financial reports and current stock price. The company's current PE Ratio is -0.05. This represents a change of -99.10% compared to the average of -5.53 of the last 4 quarters.
The mean historical PE Ratio of Biodexa Pharmaceuticals Plc over the last ten years is -10.72. The current -0.05 PE Ratio has changed -53.38% with respect to the historical average. Over the past ten years (40 quarters), BDRX's PE Ratio was at its highest in in the September 2014 quarter at 0. The PE Ratio was at its lowest in in the September 2021 quarter at -136.88.
Average
-10.72
Median
-0.12
Minimum
-57.22
Maximum
0
Discovering the peaks and valleys of Biodexa Pharmaceuticals Plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = 0
Minimum Annual Increase = 0%
Minimum Annual PE Ratio = -57.22
Year | PE Ratio | Change |
---|---|---|
2023 | -0.24 | -97.76% |
2022 | -10.51 | -81.63% |
2021 | -57.22 | 333.08% |
2020 | -13.21 | -49.31% |
2019 | -26.06 | -Infinity% |
2018 | 0 | 0% |
2017 | 0 | 0% |
2016 | 0 | 0% |
2015 | 0 | 0% |
2014 | 0 | 0% |
The current PE Ratio of Biodexa Pharmaceuticals Plc (BDRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-22.66
5-year avg
-21.45
10-year avg
-10.72
Biodexa Pharmaceuticals Plc’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biodexa Pharmaceuticals Plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biodexa Pharmaceuticals Plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Biodexa Pharmaceuticals Plc's PE Ratio?
How is the PE Ratio calculated for Biodexa Pharmaceuticals Plc (BDRX)?
What is the highest PE Ratio for Biodexa Pharmaceuticals Plc (BDRX)?
What is the 3-year average PE Ratio for Biodexa Pharmaceuticals Plc (BDRX)?
What is the 5-year average PE Ratio for Biodexa Pharmaceuticals Plc (BDRX)?
How does the current PE Ratio for Biodexa Pharmaceuticals Plc (BDRX) compare to its historical average?